# Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease

> **NCT04330079** · PHASE4 · TERMINATED · sponsor: **CHEOL WHAN LEE, M.D., Ph.D** · enrollment: 2 (actual)

## Conditions studied

- Coronary Artery Disease
- Prediabetic State

## Interventions

- **DRUG:** Dapagliflozin 10mg
- **OTHER:** Lifestyle modification

## Key facts

- **NCT ID:** NCT04330079
- **Lead sponsor:** CHEOL WHAN LEE, M.D., Ph.D
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-21
- **Primary completion:** 2021-04-08
- **Final completion:** 2021-04-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow enrollment. (Difficulty in selecting subjects)
- **Last updated:** 2022-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04330079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04330079, "Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04330079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*